E. Bacque

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

A. El-Khoueiry, S. Piha-Paul, P. Judson, 2021, Cancer Chemotherapy and Pharmacology.

An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial

Ping Wang, E. Ratner, G. Konecny, 2021, Gynecologic Oncology.

17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

K. Jardon, P. Follana, F. Heitz, 2020 .

Pharmacokinetics and safety following a single oral dose of niraparib in patients with moderate hepatic impairment.

A. El-Khoueiry, S. Piha-Paul, P. Judson, 2020 .

294 Patient-reported outcomes (PROS) in patients (PTS) receiving niraparib in the prima/engot-ov26/gog-3012 trial

B. Monk, P. Follana, Sileny N. Han, 2020 .